28013205|t|Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues
28013205|a|The aim was to establish the prevalence and severity of faecal incontinence (FI) in SSc, its association with other intestinal manifestations and potential predictors of FI, and its impact on quality of life. A multicentre, cross-sectional study of 298 SSc subjects followed in the Canadian Scleroderma Research Group cohort was performed using validated questionnaires: Jorge-Wexner score (an FI severity scale), Bristol stool scale (a visual scale of stool consistency) and FI Quality-of-Life scale. Constipation was defined by the Rome III criteria. Associations between the Jorge-Wexner score and other clinical variables were determined using multivariate regression analyses. Eighty-one (27.2%) subjects had FI, which was mild in 37 (12.4%) and moderate to severe in 44 (14.8%). Most patients had well-formed stools, 111 (38.8%) reported constipation and 38 (13.4%) had been previously treated for small intestinal bacterial overgrowth (SIBO). Variables independently associated with FI were: loose vs well-formed stools [odds ratio (OR) = 7.01, 95% CI: 2.09, 23.51)], constipation (OR = 3.64, 95% CI: 1.61, 8.27, P = 0.002), history of SIBO (OR = 2.97, 95% CI: 1.06, 8.27) and urinary incontinence (OR = 2.45, 95% CI: 1.14, 5.27). Quality of life measured with the FI Quality-of-Life scale was inversely correlated with FI severity (correlation coefficients between -0.602 and -0.702, P < 0.001). FI was common and often severe in SSc. Loose stools, SIBO, constipation and urinary incontinence were strongly associated with FI. Other than targeting anorectal dysfunction, concomitant treatment of clinical correlates could lead to improvement in FI and quality of life in SSc.
28013205	0	8	Clinical	T080	C0205210
28013205	9	19	correlates	T080	C1707520
28013205	23	42	faecal incontinence	T047	C0015732
28013205	46	64	systemic sclerosis	T047	C0036421
28013205	78	97	therapeutic avenues	UnknownType	C0679624
28013205	127	137	prevalence	T081	C0683921
28013205	142	150	severity	T080	C0392364
28013205	154	173	faecal incontinence	T047	C0015732
28013205	175	177	FI	T047	C0015732
28013205	182	185	SSc	T047	C0036421
28013205	191	202	association	T080	C0439849
28013205	214	224	intestinal	T023	C0021853
28013205	225	239	manifestations	T169	C0205319
28013205	244	253	potential	T080	C3245505
28013205	254	264	predictors	T078	C2698872
28013205	268	270	FI	T047	C0015732
28013205	280	286	impact	T080	C4049986
28013205	290	305	quality of life	T078	C0034380
28013205	322	343	cross-sectional study	T062	C0010362
28013205	351	354	SSc	T047	C0036421
28013205	355	363	subjects	T101	C0030705
28013205	380	415	Canadian Scleroderma Research Group	T093	C1708333
28013205	416	422	cohort	T098	C0599755
28013205	453	467	questionnaires	T170	C0034394
28013205	469	487	Jorge-Wexner score	T170	C0349674
28013205	492	494	FI	T047	C0015732
28013205	495	509	severity scale	T170	C0681887
28013205	512	531	Bristol stool scale	T170	C4084861
28013205	551	568	stool consistency	T033	C0426740
28013205	574	576	FI	T047	C0015732
28013205	577	598	Quality-of-Life scale	T170	C0451401
28013205	600	612	Constipation	T184	C0009806
28013205	632	649	Rome III criteria	T170	C0679228
28013205	651	663	Associations	T080	C0439849
28013205	676	694	Jorge-Wexner score	T170	C0349674
28013205	705	723	clinical variables	T033	C1836458
28013205	746	778	multivariate regression analyses	T170	C0034980
28013205	799	807	subjects	T101	C0030705
28013205	812	814	FI	T047	C0015732
28013205	826	830	mild	T080	C2945599
28013205	849	867	moderate to severe	T080	C1299393
28013205	888	896	patients	T101	C0030705
28013205	913	919	stools	T031	C0015733
28013205	942	954	constipation	T184	C0009806
28013205	979	989	previously	T079	C0205156
28013205	990	997	treated	T169	C1522326
28013205	1002	1039	small intestinal bacterial overgrowth	T047	C3160854
28013205	1041	1045	SIBO	T047	C3160854
28013205	1048	1057	Variables	T080	C0439828
28013205	1058	1071	independently	T078	C0085862
28013205	1072	1087	associated with	T080	C0332281
28013205	1088	1090	FI	T047	C0015732
28013205	1097	1102	loose	T184	C2129214
28013205	1118	1124	stools	T031	C0015733
28013205	1126	1136	odds ratio	T081	C0028873
28013205	1138	1140	OR	T081	C0028873
28013205	1154	1156	CI	T081	C0009667
28013205	1173	1185	constipation	T184	C0009806
28013205	1187	1189	OR	T081	C0028873
28013205	1202	1204	CI	T081	C0009667
28013205	1218	1219	P	T081	C1709380
28013205	1230	1237	history	T033	C0683519
28013205	1241	1245	SIBO	T047	C3160854
28013205	1247	1249	OR	T081	C0028873
28013205	1262	1264	CI	T081	C0009667
28013205	1282	1302	urinary incontinence	T046	C0042024
28013205	1304	1306	OR	T081	C0028873
28013205	1319	1321	CI	T081	C0009667
28013205	1336	1351	Quality of life	T078	C0034380
28013205	1352	1360	measured	T080	C0444706
28013205	1370	1372	FI	T047	C0015732
28013205	1373	1394	Quality-of-Life scale	T170	C0451401
28013205	1399	1408	inversely	T080	C0439850
28013205	1409	1419	correlated	T080	C1707520
28013205	1425	1427	FI	T047	C0015732
28013205	1428	1436	severity	T080	C0521117
28013205	1438	1449	correlation	T080	C1707520
28013205	1450	1462	coefficients	T081	C1707429
28013205	1490	1491	P	T081	C1709380
28013205	1502	1504	FI	T047	C0015732
28013205	1509	1515	common	T081	C0205214
28013205	1526	1532	severe	T080	C0205082
28013205	1536	1539	SSc	T047	C0036421
28013205	1541	1553	Loose stools	T184	C2129214
28013205	1555	1559	SIBO	T047	C3160854
28013205	1561	1573	constipation	T184	C0009806
28013205	1578	1598	urinary incontinence	T046	C0042024
28013205	1604	1612	strongly	T080	C0442821
28013205	1613	1628	associated with	T080	C0332281
28013205	1629	1631	FI	T047	C0015732
28013205	1644	1653	targeting	T169	C1521840
28013205	1654	1663	anorectal	T030	C3870603
28013205	1664	1675	dysfunction	T046	C0277785
28013205	1677	1688	concomitant	T079	C0521115
28013205	1689	1698	treatment	T061	C0087111
28013205	1702	1710	clinical	T080	C0205210
28013205	1711	1721	correlates	T080	C1707520
28013205	1736	1747	improvement	T077	C2986411
28013205	1751	1753	FI	T047	C0015732
28013205	1758	1773	quality of life	T078	C0034380
28013205	1777	1780	SSc	T047	C0036421